Economic evaluation for the UK of nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreas cancer

M. Gharaibeh, A. McBride, J Lyle Bootman, Ivo L Abraham

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background:The combination of nab-paclitaxel plus gemcitabine (NAB-P+GEM) has shown superior efficacy over GEM monotherapy in metastatic pancreas cancer (MPC). Independent cost-effectiveness/utility analyses of NAB-P+GEM from the payer perspective have not been conducted for the UK.Methods:A Markov model simulating the health outcomes and total costs was developed to estimate the life years gained (LYG) and quality-adjusted life years gained (QALY) and incremental cost-effectiveness (ICER) and cost-utility ratios (ICUR) for patients with MPC in a base case and in a probabilistic (PSA) sensitivity analysis. Total cost included the cost of supportive care medications, administration, chemotherapy, disease monitoring, and adverse reactions; and was discounted at 3.5% per year. A full lifetime horizon and third party payer perspective was chosen.Results:The total cost of NAB-P+GEM was £5466 higher than the cost for GEM. Respectively, LYGs were 0.97 vs 0.79 and QALYs were 0.52 vs 0.45, with ICER of £30 367/LYG and ICUR of £78 086/QALY, confirmed by PSA.Conclusions:The superior survival efficacy of NAB-P+GEM over GEM in the management of MPC is associated with positive cost-effectiveness and cost-utility.

Original languageEnglish (US)
Pages (from-to)1301-1305
Number of pages5
JournalBritish Journal of Cancer
Volume112
Issue number8
DOIs
StatePublished - Apr 14 2015

Fingerprint

gemcitabine
Pancreatic Neoplasms
Cost-Benefit Analysis
Costs and Cost Analysis
Quality-Adjusted Life Years
Therapeutics
Health Insurance Reimbursement
130-nm albumin-bound paclitaxel

Keywords

  • cost-effectiveness
  • cost-utility
  • gemcitabine
  • metastatic disease
  • nab-paclitaxel
  • pancreatic cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Economic evaluation for the UK of nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreas cancer. / Gharaibeh, M.; McBride, A.; Bootman, J Lyle; Abraham, Ivo L.

In: British Journal of Cancer, Vol. 112, No. 8, 14.04.2015, p. 1301-1305.

Research output: Contribution to journalArticle

@article{6dc9f7c471a14a0f84c7e77ecdcd2e35,
title = "Economic evaluation for the UK of nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreas cancer",
abstract = "Background:The combination of nab-paclitaxel plus gemcitabine (NAB-P+GEM) has shown superior efficacy over GEM monotherapy in metastatic pancreas cancer (MPC). Independent cost-effectiveness/utility analyses of NAB-P+GEM from the payer perspective have not been conducted for the UK.Methods:A Markov model simulating the health outcomes and total costs was developed to estimate the life years gained (LYG) and quality-adjusted life years gained (QALY) and incremental cost-effectiveness (ICER) and cost-utility ratios (ICUR) for patients with MPC in a base case and in a probabilistic (PSA) sensitivity analysis. Total cost included the cost of supportive care medications, administration, chemotherapy, disease monitoring, and adverse reactions; and was discounted at 3.5{\%} per year. A full lifetime horizon and third party payer perspective was chosen.Results:The total cost of NAB-P+GEM was £5466 higher than the cost for GEM. Respectively, LYGs were 0.97 vs 0.79 and QALYs were 0.52 vs 0.45, with ICER of £30 367/LYG and ICUR of £78 086/QALY, confirmed by PSA.Conclusions:The superior survival efficacy of NAB-P+GEM over GEM in the management of MPC is associated with positive cost-effectiveness and cost-utility.",
keywords = "cost-effectiveness, cost-utility, gemcitabine, metastatic disease, nab-paclitaxel, pancreatic cancer",
author = "M. Gharaibeh and A. McBride and Bootman, {J Lyle} and Abraham, {Ivo L}",
year = "2015",
month = "4",
day = "14",
doi = "10.1038/bjc.2015.65",
language = "English (US)",
volume = "112",
pages = "1301--1305",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Economic evaluation for the UK of nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreas cancer

AU - Gharaibeh, M.

AU - McBride, A.

AU - Bootman, J Lyle

AU - Abraham, Ivo L

PY - 2015/4/14

Y1 - 2015/4/14

N2 - Background:The combination of nab-paclitaxel plus gemcitabine (NAB-P+GEM) has shown superior efficacy over GEM monotherapy in metastatic pancreas cancer (MPC). Independent cost-effectiveness/utility analyses of NAB-P+GEM from the payer perspective have not been conducted for the UK.Methods:A Markov model simulating the health outcomes and total costs was developed to estimate the life years gained (LYG) and quality-adjusted life years gained (QALY) and incremental cost-effectiveness (ICER) and cost-utility ratios (ICUR) for patients with MPC in a base case and in a probabilistic (PSA) sensitivity analysis. Total cost included the cost of supportive care medications, administration, chemotherapy, disease monitoring, and adverse reactions; and was discounted at 3.5% per year. A full lifetime horizon and third party payer perspective was chosen.Results:The total cost of NAB-P+GEM was £5466 higher than the cost for GEM. Respectively, LYGs were 0.97 vs 0.79 and QALYs were 0.52 vs 0.45, with ICER of £30 367/LYG and ICUR of £78 086/QALY, confirmed by PSA.Conclusions:The superior survival efficacy of NAB-P+GEM over GEM in the management of MPC is associated with positive cost-effectiveness and cost-utility.

AB - Background:The combination of nab-paclitaxel plus gemcitabine (NAB-P+GEM) has shown superior efficacy over GEM monotherapy in metastatic pancreas cancer (MPC). Independent cost-effectiveness/utility analyses of NAB-P+GEM from the payer perspective have not been conducted for the UK.Methods:A Markov model simulating the health outcomes and total costs was developed to estimate the life years gained (LYG) and quality-adjusted life years gained (QALY) and incremental cost-effectiveness (ICER) and cost-utility ratios (ICUR) for patients with MPC in a base case and in a probabilistic (PSA) sensitivity analysis. Total cost included the cost of supportive care medications, administration, chemotherapy, disease monitoring, and adverse reactions; and was discounted at 3.5% per year. A full lifetime horizon and third party payer perspective was chosen.Results:The total cost of NAB-P+GEM was £5466 higher than the cost for GEM. Respectively, LYGs were 0.97 vs 0.79 and QALYs were 0.52 vs 0.45, with ICER of £30 367/LYG and ICUR of £78 086/QALY, confirmed by PSA.Conclusions:The superior survival efficacy of NAB-P+GEM over GEM in the management of MPC is associated with positive cost-effectiveness and cost-utility.

KW - cost-effectiveness

KW - cost-utility

KW - gemcitabine

KW - metastatic disease

KW - nab-paclitaxel

KW - pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=84928208892&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928208892&partnerID=8YFLogxK

U2 - 10.1038/bjc.2015.65

DO - 10.1038/bjc.2015.65

M3 - Article

VL - 112

SP - 1301

EP - 1305

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 8

ER -